SCHEMBL24855219

SCHEMBL24855219

Cc1cccc(-c2ccc3c(c2)OCC(=O)N3)c1C

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 9/20 0.61
CYP11B1 P15538 2/20 0.54
CYP11B2 P19099 2/20 0.54
NR3C2 P08235 1/20 0.52
PKM P14618 2/20 0.51
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49
GRIA1 P42261 1/20 0.48
CACNG8 Q8WXS5 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MMP12 P39900 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24855141 0.87 NSD2 (0.56) NSD2CYP11B1CYP11B2NR3C2PKM
SCHEMBL30800907 0.81 CYP11B1 (0.56) NSD2CYP11B1CYP11B2NR3C2PDE3B
SCHEMBL24855582 0.81 CYP11B1 (0.56) NSD2CYP11B1CYP11B2NR3C2PDE3B
SCHEMBL6603981 0.78 CYP11B1 (0.56) NSD2CYP11B1CYP11B2PDE3BPDE3A
SCHEMBL19188092 0.77 MMP12 (0.62) NSD2CYP11B1CYP11B2NR3C2PKM
SCHEMBL30494449 0.77 CYP11B1 (0.64) NSD2CYP11B1CYP11B2PDE3BPDE3A
SCHEMBL26463265 0.77 CYP11B1 (0.64) NSD2CYP11B1CYP11B2PDE3BPDE3A
SCHEMBL20111135 0.77 GRIA1 (0.79) CYP11B1CYP11B2PDE3BPDE3AGRIA1
SCHEMBL6297092 0.74 CYP11B1 (0.64) NSD2CYP11B1CYP11B2NR3C2PDE3B
SCHEMBL280003 0.74 MMP12 (0.75) CYP11B1CYP11B2PKMPDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023272720-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS Ascletis BioScience Co., Ltd (CN) 2023-01-05 WO disclosed